Cingulate Inc. (CING) Stock Analysis & Investment Frameworks
Cingulate Inc. (CING) stock analysis on Invetso. Review Cingulate Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Cingulate Inc. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Cingulate Inc. Key Financial Metrics
- Market Cap: $61.95M
- Revenue: $N/A
- ROE: -238.41%
- ROIC: -83.74%
- Dividend Yield: N/A
About Cingulate Inc.
Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its pipeline for ADHD are two drug candidates: CTx-1301 (dexmethylphenidate), which is currently progressing through Phase 3 clinical trials, and CTx-1302 (dextroamphetamine). The company is also engaged in the advancement of CTx-2103, a candidate intended for the management of anxiety disorders. Founded in 2012, Cingulate Inc. maintains its corporate headquarters in Kansas City, Kansas.
Cingulate Inc. Investment Frameworks
Invetso analyzes Cingulate Inc. (CING) across the following frameworks:
- Cingulate Inc. 10Y Growth Potential
- Cingulate Inc. Scenario Analysis
- Cingulate Inc. Risks & Opportunities
- Cingulate Inc. Economic Moat
- Cingulate Inc. Business Model
- Cingulate Inc. Management
- Cingulate Inc. SWOT Analysis
- Cingulate Inc. Porter's 5 Forces
- Cingulate Inc. PESTLE Analysis
- Cingulate Inc. ESG Analysis